27 assets in BRCA2-Related Cancer Predisposition

Therapeutic assets addressing BRCA2-Related Cancer Predisposition, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Talazoparib BRCA2-Related Cancer Predisposition	Brown University	P3	BB (68)
Olaparib BRCA2-Related Cancer Predisposition	GBG Forschungs GmbH	P3	BB (67)
Niraparib BRCA2-Related Cancer Predisposition	Qian Qin	P3	BB (64)
Carboplatin BRCA2-Related Cancer Predisposition	Okayama University	P2	B (61)
Metformin BRCA2-Related Cancer Predisposition	Alliance for Clinical Trials in Oncology	P3	B (60)
Irinotecan BRCA2-Related Cancer Predisposition	University of California, San Francisco	P2	B (58)
Docetaxel BRCA2-Related Cancer Predisposition	Qian Qin	P2	B (57)
Durvalumab BRCA2-Related Cancer Predisposition	European Organisation for Research and Treatment of Cancer - EORTC	P2	B (57)
Abiraterone BRCA2-Related Cancer Predisposition	Qian Qin	P2	CCC (53)
Cediranib BRCA2-Related Cancer Predisposition	M.D. Anderson Cancer Center	P2	CCC (53)
Ceralasertib BRCA2-Related Cancer Predisposition	M.D. Anderson Cancer Center	P2	CCC (53)
Deslorelin BRCA2-Related Cancer Predisposition	City of Hope Medical Center	P2	CCC (53)
Dostarlimab BRCA2-Related Cancer Predisposition	Dana-Farber Cancer Institute	P2	CCC (53)
Elacestrant BRCA2-Related Cancer Predisposition	GBG Forschungs GmbH	P2	CCC (53)
Exemestane BRCA2-Related Cancer Predisposition	Dana-Farber Cancer Institute	P2	CCC (53)
Pembrolizumab BRCA2-Related Cancer Predisposition	Okayama University	P2	CCC (53)
Prednisone BRCA2-Related Cancer Predisposition	Qian Qin	P2	CCC (53)
Tamoxifen BRCA2-Related Cancer Predisposition	Dana-Farber Cancer Institute	P2	CCC (53)
Testosterone Undecylate BRCA2-Related Cancer Predisposition	City of Hope Medical Center	P2	CCC (53)
Ace-86225106 BRCA2-Related Cancer Predisposition	Acerand Therapeutics (Shanghai) Limited	P1/2	CC (45)
Etx-19477 BRCA2-Related Cancer Predisposition	858 Therapeutics, Inc.	P1/2	CC (45)
Capivasertib BRCA2-Related Cancer Predisposition	M.D. Anderson Cancer Center	P1	CC (43)
Vistusertib BRCA2-Related Cancer Predisposition	M.D. Anderson Cancer Center	P1	CC (43)
Aquocobalamin BRCA2-Related Cancer Predisposition	General Oncology, Inc.	P1	CC (41)
Camustine BRCA2-Related Cancer Predisposition	General Oncology, Inc.	P1	CC (41)
Immunoglobulin G4, Anti-(Human Colony-Stimulating Factor 1 Receptor) (Human-Rattus Norvegicus Monoclonal Sndx-6352 .Gamma.4-Chain), Disulfide With Human-Rattus Norvegicus Monoclonal Sndx-6352 .Kappa.-Chain, Dimer BRCA2-Related Cancer Predisposition	Dana-Farber Cancer Institute	P1	CC (41)
Melphalan BRCA2-Related Cancer Predisposition	General Oncology, Inc.	P1	CC (41)